Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan

In Japan, 1.5–2 million people are chronically infected with hepatitis C virus (HCV) infection. New direct-acting antiviral agents (DAA) offer an unprecedented opportunity to cure HCV. While the price of HCV treatment decreased recently in most countries, it remains one of the highest in Japan. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Yueran, Hayashi, Tomoyuki, Chen, Qiushi, Aggarwal, Rakesh, Hutin, Yvan, Chhatwal, Jagpreet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058050/
https://www.ncbi.nlm.nih.gov/pubmed/32139872
http://dx.doi.org/10.1038/s41598-020-60986-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058050/
https://www.ncbi.nlm.nih.gov/pubmed/32139872
http://dx.doi.org/10.1038/s41598-020-60986-4

Ejemplares similares